1
|
Wang X, Zhao J, Hu Y, Jiao Z, Lu Y, Ding M, Kou Y, Li B, Meng F, Zhao H, Li H, Li W, Yang Y, Lv L. Sodium nitroprusside treatment for psychotic symptoms and cognitive deficits of schizophrenia: A randomized, double-blind, placebo-controlled trial. Psychiatry Res 2018; 269:271-277. [PMID: 30170285 DOI: 10.1016/j.psychres.2018.08.079] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/01/2017] [Revised: 07/07/2018] [Accepted: 08/19/2018] [Indexed: 11/24/2022]
Abstract
Schizophrenia presents with a broad range of negative, positive, and cognitive symptoms, and comprehensive treatment is still a challenge. Sodium nitroprusside (SNP) has been reported to rapidly reduce psychotic symptoms and improve cognitive functions in patients with schizophrenia, providing a new possible direction for treatment. In this study, we tested whether SNP can improve psychotic symptoms and cognitive function in schizophrenia patients with longer disease history. This was a randomized, double-blind, placebo-controlled trial conducted between May 2016 and April 2017. Forty-two schizophrenia patients aged 18-45 years were recruited from Henan Province Mental Hospital. Baseline psychiatric symptoms were measured using the Positive and Negative Syndrome Scale (PANSS), and baseline cognitive functions were measured using the Wechsler Adult Intelligence Scale. Patients received two SNP or placebo infusions (0.5 μg/kg per min for 4 h) at a one-week interval. We reassessed psychiatric symptoms and cognitive functions using the same tests shortly after the first and second infusions and 4 weeks after the second infusion. We did not find any significant effect of SNP over placebo on psychotic symptoms or cognitive functions, although SNP was relatively well tolerated with a good safety profile.
Collapse
Affiliation(s)
- Xiujuan Wang
- Department of Psychiatry, Henan Mental Hospital, The Second Affiliated Hospital of Xinxiang Medical University, Xinxiang, China; Henan Key Lab of Biological Psychiatry, Xinxiang Medical University, Xinxiang, China
| | - Jingyuan Zhao
- Department of Psychiatry, Henan Mental Hospital, The Second Affiliated Hospital of Xinxiang Medical University, Xinxiang, China
| | - YunQing Hu
- Department of Psychiatry, Henan Mental Hospital, The Second Affiliated Hospital of Xinxiang Medical University, Xinxiang, China; Henan Key Lab of Biological Psychiatry, Xinxiang Medical University, Xinxiang, China
| | - Zhiqiang Jiao
- Department of Psychiatry, Henan Mental Hospital, The Second Affiliated Hospital of Xinxiang Medical University, Xinxiang, China
| | - Yanli Lu
- Department of Psychiatry, Henan Mental Hospital, The Second Affiliated Hospital of Xinxiang Medical University, Xinxiang, China
| | - Minli Ding
- Department of Psychiatry, Henan Mental Hospital, The Second Affiliated Hospital of Xinxiang Medical University, Xinxiang, China
| | - Yanna Kou
- Department of Psychiatry, Henan Mental Hospital, The Second Affiliated Hospital of Xinxiang Medical University, Xinxiang, China
| | - Benliang Li
- Department of Psychiatry, Henan Mental Hospital, The Second Affiliated Hospital of Xinxiang Medical University, Xinxiang, China; Henan Key Lab of Biological Psychiatry, Xinxiang Medical University, Xinxiang, China
| | - Fancui Meng
- Department of Psychiatry, Henan Mental Hospital, The Second Affiliated Hospital of Xinxiang Medical University, Xinxiang, China
| | - Hongzu Zhao
- Department of Psychiatry, Henan Mental Hospital, The Second Affiliated Hospital of Xinxiang Medical University, Xinxiang, China
| | - Hong Li
- Department of Psychiatry, Henan Mental Hospital, The Second Affiliated Hospital of Xinxiang Medical University, Xinxiang, China
| | - Wenqiang Li
- Department of Psychiatry, Henan Mental Hospital, The Second Affiliated Hospital of Xinxiang Medical University, Xinxiang, China; Henan Key Lab of Biological Psychiatry, Xinxiang Medical University, Xinxiang, China
| | - Yongfeng Yang
- Department of Psychiatry, Henan Mental Hospital, The Second Affiliated Hospital of Xinxiang Medical University, Xinxiang, China; Henan Key Lab of Biological Psychiatry, Xinxiang Medical University, Xinxiang, China
| | - Luxian Lv
- Department of Psychiatry, Henan Mental Hospital, The Second Affiliated Hospital of Xinxiang Medical University, Xinxiang, China; Henan Key Lab of Biological Psychiatry, Xinxiang Medical University, Xinxiang, China.
| |
Collapse
|
2
|
Jonkman K, van der Schrier R, van Velzen M, Aarts L, Olofsen E, Sarton E, Niesters M, Dahan A. Differential role of nitric oxide in the psychedelic symptoms induced by racemic ketamine and esketamine in human volunteers. Br J Anaesth 2018; 120:1009-1018. [DOI: 10.1016/j.bja.2018.01.022] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/28/2017] [Revised: 01/08/2018] [Accepted: 01/29/2018] [Indexed: 12/21/2022] Open
|
3
|
Rezende TMN, Maia-de-Oliveira JP, Kandratavicius L, Machado-de-Sousa JP, Abrão J, Prado DA, Bressan RA, Lacerda ALT, Zuardi AW, Baker GB, Dursun SM, Hallak JEC. Effects of sodium nitroprusside in the prevention of schizophrenia-like symptoms induced by ketamine – A translational double-blind study. ACTA ACUST UNITED AC 2017. [DOI: 10.1590/0101-60830000000141] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/25/2023]
Affiliation(s)
| | - João Paulo Maia-de-Oliveira
- National Institute of Science and Technology – Translational Medicine, Brazil; Federal University of Rio Grande do Norte, Brazil
| | | | - João Paulo Machado-de-Sousa
- University of São Paulo, Brazil; National Institute of Science and Technology – Translational Medicine, Brazil
| | | | | | | | | | - Antonio W. Zuardi
- University of São Paulo, Brazil; National Institute of Science and Technology – Translational Medicine, Brazil
| | - Glen B. Baker
- National Institute of Science and Technology – Translational Medicine, Brazil; University of Alberta, Canada
| | - Serdar M. Dursun
- National Institute of Science and Technology – Translational Medicine, Brazil; University of Alberta, Canada
| | - Jaime E. C. Hallak
- University of São Paulo, Brazil; National Institute of Science and Technology – Translational Medicine, Brazil
| |
Collapse
|
5
|
Cetin M, Aricioglu F. Unmet needs in psychiatry and emerging novel pharmacological agents. ACTA ACUST UNITED AC 2016. [DOI: 10.5455/bcp.20130927064824] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Affiliation(s)
- Mesut Cetin
- Klinik Psikofarmakoloji Bülteni-Bulletin of Clinical Pychopharmacology, GATA Haydarpasa Training Hospital, Department of Psychiatry, Istanbul-Turkey
| | - Feyza Aricioglu
- Marmara University, School of Pharmacy Department of Pharmacology and Psychopharmacology Research Unit, Istanbul-Turkey
| |
Collapse
|
6
|
Maia-de-Oliveira JP, Lobão-Soares B, Ramalho T, Gavioli EC, Soares VP, Teixeira L, Baker GB, Dursun SM, Hallak JEC. Nitroprusside single-dose prevents the psychosis-like behavior induced by ketamine in rats for up to one week. Schizophr Res 2015; 162:211-5. [PMID: 25586741 DOI: 10.1016/j.schres.2014.12.035] [Citation(s) in RCA: 22] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/21/2014] [Revised: 12/19/2014] [Accepted: 12/22/2014] [Indexed: 11/30/2022]
Abstract
Recently, we found a rapid and long-lasting improvement of symptoms in schizophrenic patients on antipsychotics after a single four-hour infusion of sodium nitroprusside (SNP), a nitric oxide (NO) donor with a short half-life. This improvement persisted for up to 4weeks. Because these patients remained on antipsychotics after infusion of SNP was finished, the question arises about whether this improvement was due to SNP itself. We have now investigated whether SNP, alone, can produce preventive antipsychotic effects in rats treated with ketamine (KET). 56 adult rats divided into 7 groups were infused with SNP 4mg/kg, KET 25mg/kg, or saline as follows: group1 - saline, group2 - SNP, group3 - KET, group4 - KET 12h after SNP, group5 - KET 1day after SNP, group6 - KET 2days after SNP, and group7 - KET 1week after SNP. The animals were filmed in an open field arena for 30min and the videos were later analyzed by ANY-Maze software to measure activity and stereotypy. SNP significantly prevented the emergence of hyperactivity induced by KET when it was administered for up to 1week before KET, and prevented the emergence of stereotypies when it was administered for up to 1day before KET. These findings in rats, which have an even faster metabolic rate than humans, suggest that the long-lasting effects observed in our clinical trial with SNP in humans could have been due to SNP itself, and indicate for the first time that SNP may present preventive antipsychotic effects.
Collapse
Affiliation(s)
- Joao Paulo Maia-de-Oliveira
- Department of Neuroscience and Behavioral Science, University of Sao Paulo (USP) - Ribeirao Preto, SP CEP 14048-900, Brazil; Department of Clinical Medicine, Federal University of Rio Grande do Norte, Natal, RN CEP 59012420, Brazil.
| | - Bruno Lobão-Soares
- Department of Biophysics and Pharmacology, Federal University of Rio Grande do Norte (UFRN), Natal, RN, CEP 59012420, Brazil
| | - Thais Ramalho
- Department of Biophysics and Pharmacology, Federal University of Rio Grande do Norte (UFRN), Natal, RN, CEP 59012420, Brazil
| | - Elaine C Gavioli
- Department of Biophysics and Pharmacology, Federal University of Rio Grande do Norte (UFRN), Natal, RN, CEP 59012420, Brazil
| | - Vanessa Paula Soares
- Department of Biophysics and Pharmacology, Federal University of Rio Grande do Norte (UFRN), Natal, RN, CEP 59012420, Brazil
| | - Leslie Teixeira
- Department of Biophysics and Pharmacology, Federal University of Rio Grande do Norte (UFRN), Natal, RN, CEP 59012420, Brazil
| | - Glen B Baker
- Neurochemical Research Unit, Department of Psychiatry, University of Alberta, 12-105B CSB, Edmonton, AB T6G 2G3, Canada
| | - Serdar M Dursun
- Neurochemical Research Unit, Department of Psychiatry, University of Alberta, 12-105B CSB, Edmonton, AB T6G 2G3, Canada
| | - Jaime E C Hallak
- Department of Neuroscience and Behavioral Science, University of Sao Paulo (USP) - Ribeirao Preto, SP CEP 14048-900, Brazil
| |
Collapse
|